DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...

Many common conditions linked to aging develop without symptoms for years. Learn which five pose the biggest risks and the ...

Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...

After several challenging quarters, Regeneron's sales growth is rebounding. In the first quarter, the company's revenue rose ...

"The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President, CEO & Director Jay ...

Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ...

Dr. Tory Prestera and Dr. Howard Guan share key differences between dry and wet macular degeneration, including common symptoms, causes, and treatment options. Dry macular degeneration is the more ...

NEW HAVEN, Conn. (WTNH) — In today’s health headlines, we’re focusing on eye health. February is Low Vision and Macular Degeneration Awareness Month. Dr. Vicente Diaz, Yale Medicine ophthalmologist ...

As we grow older, our eyes naturally undergo changes, but certain conditions need extra care. One of the most prevalent and serious vision issues for older adults is Age-Related Macular Degeneration ...